Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer.

ABSTRACT:

SUBMITTER: Nakai H 

PROVIDER: S-EPMC10061489 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature